z-logo
open-access-imgOpen Access
Rethinking thresholds for serological evidence of influenza virus infection
Author(s) -
Zhao Xiahong,
Siegel Karen,
Chen Mark ICheng,
Cook Alex R.
Publication year - 2017
Publication title -
influenza and other respiratory viruses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.743
H-Index - 57
eISSN - 1750-2659
pISSN - 1750-2640
DOI - 10.1111/irv.12452
Subject(s) - serology , bivariate analysis , herd immunity , medicine , virology , outbreak , attack rate , statistics , immunology , vaccination , antibody , mathematics
For pathogens such as influenza that cause many subclinical cases, serologic data can be used to estimate attack rates and the severity of an epidemic in near real time. Current methods for analysing serologic data tend to rely on use of a simple threshold or comparison of titres between pre‐ and post‐epidemic, which may not accurately reflect actual infection rates. Methods We propose a method for quantifying infection rates using paired sera and bivariate probit models to evaluate the accuracy of thresholds currently used for influenza epidemics with low and high existing herd immunity levels, and a subsequent non‐influenza period. Pre‐ and post‐epidemic sera were taken from a cohort of adults in Singapore (n=838). Bivariate probit models with latent titre levels were fit to the joint distribution of haemagglutination‐inhibition assay‐determined antibody titres using Markov chain Monte Carlo simulation. Results Estimated attack rates were 15% (95% credible interval: 12%‐19%) for the first H1N1 pandemic wave. For a large outbreak due to a new strain, a threshold of 1:20 and a twofold rise (if pared sera is available) would result in a more accurate estimate of incidence. Conclusion The approach presented here offers the basis for a reconsideration of methods used to assess diagnostic tests by both reconsidering the thresholds used and by analysing serological data with a novel statistical model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here